5/30 Webinar: Community & Stakeholder Input to Inform the Future of HIV Research

Date: Thursday, May 30, 2024
Time: 12:00pm EST


Every seven years, the National Institutes of Health (NIH) engages in a process that will help determine the focus and priorities of its global HIV clinical trials research networks. As part of this “network competition,” the NIH reviews the structure and funding of its HIV clinical research networks. A critical part of this process involves community and stakeholder input to help inform future research priorities.

The Office of HIV/AIDS Network Coordination (HANC) invites you to join conversations with Dr. Carl Dieffenbach, Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) about the future of global HIV research. 

Click to Register

This online seminar will feature a brief presentation from Dr. Dieffenbach followed by a Q&A session.

We invite you to click on the following link to provide any questions/comments that you may have in advance for Dr. Dieffenbach; these should be related to your thoughts on the network competition and future HIV research priorities. We plan to include sufficient time for questions to arise as part of the conversation.



Dr. Carl Dieffenbach, Ph.D.
Serves as Director of the Division of AIDS (DAIDS). Dr. Dieffenbach oversees a global HIV/AIDS research portfolio of more than $1 billion and a staff of more than 150 federal employees. Dr. Dieffenbach is responsible for planning, implementing, managing, and evaluating divisional programs in the following areas:

  1. Basic laboratory research
  2. Discovery and development of therapies and treatment strategies for HIV infection, related co-infections and co-morbidities, and the complications associated with treated HIV disease through basic research and clinical trials
  3. Discovery and development of vaccines, topical microbicides, and other prevention strategies through basic research and clinical trials

Dr. Dieffenbach played a key role in restructuring the DAIDS-supported clinical trials research networks and has actively fostered collaboration and partnerships with other federal agencies, international research organizations, professional societies, foundations, community advocacy groups, and industry.